ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2464

Multidisciplinary Unit of Psoriatic Arthritis: Clinical Results

Clara Pérez-Velásquez1, Oihane Ibarguengoitia-Barrena 2, David Montero-Seisdedos 2, Lucía Vega-Alvarez 2, Carmen García-Gómez 1, Eva Galindez-Agirregoikoa 3, Silvia Pérez-Barrio 4, María Esther Ruiz-Lucea 2, Ignacio Torre-Salaberri 2, Ana Rosa Intxaurbe-Pellejero 2, Olaia Fernandez-Berrizbeitia 1, Juan María Blanco-Madrigal 2, Eduardo Cuende-Quintana 2, Itziar Calvo-Zorrilla 2, Iñigo Gorostiza-Hormaeche 5, Natalia Andrea Rivera-García 2, María Jesus Allande-López-Linares 2, Helena Ugarte-Zuazo 2 and María García-Vivar 1, 1University Hospital of Basurto, Bilbao, Pais Vasco, Spain, 2Rheumatology Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain, 3Hospital de Basurto, Bilbao, Pais Vasco, Spain, 4University Hospital of Basurto, Dermatology Department, Bilbao, Pais Vasco, Spain, 5Investigation Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biologic drugs, multidisciplinary unit, psoriasis and DMARDs, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The multidisciplinary unit of psoriatic arthritis (PsA) are attractive to improve the early diagnosis and optimize the management of complex patients with PsA. There are published data about different models, activity data and patient satisfaction in this kind os unit. To evaluate its effectiveness, we also need to know the clinical results of patients with PsA who visit them.

The objective of this study is to evaluate the control of the cutaneous and articular activity of the patients with psoriatic arthritis in our multidisciplinary unit.

Methods: We reviewed 199 medical records and included 132 patients with peripheral, mixed or axial PsA, treated with DMARDs or biological therapy (TB), followed up for at least 6 months in our unit. Epidemiological, clinical and skin and joint activity  data are collected, evaluating DAPSA, PASI, BSA, PGA and percentage of patients that reach MDA (minimal disease activity). The data is analyzed using SPSSv23.

Results: 132 patients, 65.2% males, with a mean age (SD) of 54.98 (13.99) years, and a time of evolution of 110.37 months (SD 89.77). Diagnosis: 65.9% peripheral PsA, 30.3% mixed and 3.8% pure axial involvement. 68.2% had one comorbidity and 27.3% two or more. 56.8% had a family history of psoriasis and 19.7% of PsA. The presentation of psoriasis was predominantly in plaques (81.8%) and 8.3% in folds. 36.4% had previous enthesitis, 39.4% previous dactylitis. 68.2% had received one DMARD, 37.1% two or more. 22% had received previous biological therapy and 10.6% had received at least two biological drugs. Current treatment: 57 patients (43.1%) received BT and 75 patients received DMARD (only 2.3% receive two DMARDs). BT: 30.3% anti-TNF, 6.1% Ustekinumab, 3.8% Secukinumab and 3.8% Apremilast. Time of current treatment in months: mean 59.79 (SD 58.87).   Cutaneous and joint activity: median of DAPSA 3.53 (0.06-54.50), PASI 2 (0-13) and BSA 2 (0-18). PGA from very mild to mild 83.6%, mild PASI 79% and mild BSA 52%. DAPSA of low activity 90.1% and DAPSA of remission (< 4) 59.2%. 62.4% of the patients reached MDA criteria.

Conclusion: We consider that the clinical results of the patients visited in our multidisciplinary clinic are in general, good or very good, even in the subgroup of more complex patients. It would be necessary to carry out an additional cost study to assess its efficiency.


ACR Unit tabla1

Cutaneous and joint activity


ACR Unit tabla2

Outcome measures


Disclosure: C. Pérez-Velásquez, None; O. Ibarguengoitia-Barrena, None; D. Montero-Seisdedos, None; L. Vega-Alvarez, None; C. García-Gómez, None; E. Galindez-Agirregoikoa, None; S. Pérez-Barrio, None; M. Ruiz-Lucea, None; I. Torre-Salaberri, None; A. Intxaurbe-Pellejero, None; O. Fernandez-Berrizbeitia, None; J. Blanco-Madrigal, None; E. Cuende-Quintana, None; I. Calvo-Zorrilla, None; I. Gorostiza-Hormaeche, None; N. Rivera-García, None; M. Allande-López-Linares, None; H. Ugarte-Zuazo, None; M. García-Vivar, None.

To cite this abstract in AMA style:

Pérez-Velásquez C, Ibarguengoitia-Barrena O, Montero-Seisdedos D, Vega-Alvarez L, García-Gómez C, Galindez-Agirregoikoa E, Pérez-Barrio S, Ruiz-Lucea M, Torre-Salaberri I, Intxaurbe-Pellejero A, Fernandez-Berrizbeitia O, Blanco-Madrigal J, Cuende-Quintana E, Calvo-Zorrilla I, Gorostiza-Hormaeche I, Rivera-García N, Allande-López-Linares M, Ugarte-Zuazo H, García-Vivar M. Multidisciplinary Unit of Psoriatic Arthritis: Clinical Results [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/multidisciplinary-unit-of-psoriatic-arthritis-clinical-results/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multidisciplinary-unit-of-psoriatic-arthritis-clinical-results/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology